1. US market growth recovers to 4.2% in MAT November YTD Growth is 4.8% Source: IMS Health, National Sales Perspectives, Nov. 2009

2. US prescription growth recovers to 2.5% MAT November 2009 YTD Growth is 2.1% Source: IMS Health, National Prescription Audit Plus, Nov. 2009

4. Patent expiries

5. Slow uptake of recently launched products

6. Greater substitution of generics

7. Protected brands price growth

8. Increasing generic volume and less price deflation

9. Approvals of innovative therapies

10. Few notable safety events

11. Demographic factorsSource: IMS Health, Market Prognosis, IMS Consulting, Sep 2009

12. Branded Generics Disaggregated TRx growth brands and generics Source: IMS Health, National Prescription Audit, Nov 2009, Branded generics disaggregated

13. Branded Generics Disaggregated Sales and TRx share brands and generics Source: IMS Health, National Sales Perspectives, Nov 2009, National Prescription Audit, Nov 2009, Branded generics disaggregated

14. $91 billion opportunity in the US through 2013 Value of products at risk 2003-2013 Source: IMS Health, MIDAS, Market Segmentation, MAT Jun 2009

16. Efient

17. Entereg

18. Multaq

19. Promacta

20. Simponi

21. Vimpat24 REMS Apr-Dec 2008 31 REMS Jan-Jul 2009 COUNT OF BLACKBOX WARNINGS Source: FDA MedWatch, Oct 2009

22. FDA approvals in 2008 are skewed towards specialist driven and niche therapies NUMBER OF NCE LAUNCHES Source: FDA, IMS Health, Market Insights Team Analysis, Oct 2009

23. Growth is strong in classes not impacted by patent expiration or safety Source: IMS Health, National Sales Perspectives, Sep 2009

24. Double-digit growth very common in next tier therapy classes Source: IMS Health, National Sales Perspectives, Sep 2009

25. Absolute growth – top 10 therapies Source: IMS Health, National Sales Perspectives, National Prescription Audit, Sep 2009